The impact of subcutaneous glucagon before, during and after exercise. A study in patients with type 1 diabetes mellitus - The impact of a glucagon injection before, during and after exercise

Hvidovre University Hospital0 个研究点开始时间: 2016年5月31日最近更新: 2017年8月21日

试验速览

暂无简介。

•Age 18 - 70 years
•- T1D = 2 year
•- BMI 20-30 kg/m2
•- Insulin pump = 1 year.
•- HbA1c < 69 mmol/mol (8.5 %)
•- Hypoglycemia awareness (reported by Gold et al.)
•- Use of carbohydrate counting and the insulin pump bolus calculator for all meals
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 14
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Allergy or intolerance to lactose or GlucaGen® (Novo Nordisk, Bagsværd, DK)
•- Impaired renal function (eGFR < 60 ml/min/1.73m2)
•- Liver disease with ALAT > 2.5 times the upper limit of the reference interval
•- Use of anti-diabetic medicine (other than insulin), per oral corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
•- Known or suspected alcohol or drug abuse
•- Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
•- Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
•- Inability to understand the patient information and to give informed consent
•- Physical or mental incapacity to perform exercise
•-People with vigorous intensity aerobic physical activity such as swimming, jogging, aerobics, football, tennis, gym, workout etc, more than 3 hours or more per week.
•- Chronic use or unable to stop acetaminophen (paracetamol) use
•-Allergy to the patch of CGM sensors

发起方